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Introduction
Medication-related problems are a significant contributor to morbidity, mortality and health care resource utilization in Canada and around the world. [1] [2] [3] [4] [5] Many jurisdictions in Canada and elsewhere have adopted policies and programs to encourage greater pharmacist responsibility for medication management, including collaboration with other health care providers. [6] [7] [8] [9] [10] Since 2007, community pharmacies in Ontario have been compensated for pharmacistconducted adherence-focused medication
Original research reviews (MedsChecks) with Ontario residents who take 3 or more prescription medications for chronic conditions. The MedsCheck Annual (MCA) service is a one-to-one consultation in a community pharmacy that is intended to take approximately 20 to 30 minutes. The service can be provided every 12 months. Its purpose is to help patients better understand their medications, ensure that medications are being taken as prescribed and provide patients with a comprehensive list of their prescription and nonprescription medications. 11 Pharmacies were paid $950 upon submission of their first MCA claim to cover service start-up costs and $50 per MCA (thereafter raised to $60 per MCA in June 2010). 12 The MCA service was the first nondispensing pharmacy service to be reimbursed by the Ontario public drug plan. 13 It was launched 9 months after a Ministry of Health policy that banned generic drug manufacturers' rebates to pharmacies for purchases of their products and decreased by about 25% the amount that the drug plan would pay pharmacies for generic drugs. 14, 15 Since 2007, the drug plan has expanded its reimbursement of medication review services to include MedsCheck Diabetes, MedsCheck at Home and MedsCheck Long-Term Care, as well as follow-ups for all but MC at Home. MedsCheck was the second medication review service to be reimbursed by any provincial drug plan in Canada, with the first being Quebec, which included a medication review for persons taking at least 8 medications in its pharmaceutical opinion program. 16 Medication review services are currently funded in most jurisdictions in Canada, including Ontario, Alberta, British Columbia, Saskatchewan, New Brunswick, Newfoundland and Nova Scotia. Ontario has spent more than $130 million on MCA between inception and March 2013.
Evaluation of the MCA program has been limited. A study of Hamilton area pharmacists' early implementation experience found that the program was well received. 17 However, numerous barriers to implementation were identified, most notably lack of time and pharmacy workflow that was not conducive to an appointment-based, 30-minute service. 17 A recent population-based cohort study examined claims for all MedsCheck programs for the 2012-2013 fiscal year and found that 27.1% (n = 799,674) of Ontarians eligible for public drug coverage (primarily those older than 65 years) received a professional pharmacy service, with 64% (n = 511,490) of these receiving an MCA. 18 The study also found that as patient complexity (number of prescription medications in the past year) increased, the proportion of Ontario Drug Benefit (ODB) beneficiaries who received a professional pharmacy service, which included a MedsCheck or a Pharmaceutical Opinion, also increased. 18 The Pharmaceutical Opinion Program in Ontario refers to the identification by the pharmacist of a potential drugrelated problem during the course of dispensing a new or repeat prescription or when conducting a MedsCheck medication review. 19 With a Pharmaceutical Opinion, based on consultation with the prescriber, the prescription therapy may not be dispensed, may be dispensed as prescribed or a prescription therapy may be adjusted. 19 This study did not examine the characteristics of MCA recipients or trends in service delivery over time, however. A more comprehensive analysis of the uptake of the MCA service (the first and most popular of the MC services) is warranted. It could help clinicians and policy makers understand service uptake and gaps to better direct future delivery of services. Also, trends in service utilization over time can help forecast service use and the associated benefits, costs and resultant value to the health care system. 
Methods

Study design
We conducted a population-based cohort study of MCA recipients using linked administrative data housed at the Institute for Clinical Evaluative Sciences ( Residents of long-term care facilities, those with missing sex data or those whose death date was prior to enrolment were excluded. Residents of long-term care facilities were excluded because they were not eligible for a MedsCheck Annual. On September 13, 2010, Ontario added MedsCheck for Long-Term Home Residents, MedsCheck at Home and MedsCheck for Ontarians Living with Diabetes. Populations served by the later 2 services may have received a MedsCheck Annual before September 13, 2010.
Measures
The number of unique patients receiving and unique pharmacies providing MCA services over time were counted. The following characteristics of MCA service recipients were described: age, sex, region of residence, immigrant status, prior use of professional pharmacy services, comorbidities, prior prescription drug use and number of drugs dispensed; at index date, 30 days before index and 1-year before index date. Certain comorbidities (hypertension, myocardial infarction, heart failure, diabetes, chronic obstructive pulmonary disease, asthma and psychiatric disorders) were established using validated diagnosis identifiers developed at ICES. Other comorbidities (cancer, arthritis, cerebrovascular disease and fracture) were derived from combinations of OHIP billing codes used in previous ICES analyses and reviewed by the team for face validity. Evidence supporting the validation of disease algorithms or health condition coding is available by searching the ICES website (www.ices.on.ca). Level of comorbidity was defined using John Hopkins Adjusted Clinical Groups (ACG) resource utilization bands. 20, 21 ACG methodology generates a measure of an individual's medical complexity based on groups of diagnoses. Diagnostic information from the administrative databases was used to categorize MCA recipients into 1 of 6 resource utilization bands, which range from 0 (nonusers; lowest expected health care costs) to 5 (very high users; highest expected health care costs). Highcost users of medications were defined as having ODB prescription drug claims for $4000 or more in the previous year. 22 
MIsE EN PrAtIQUE DEs cONNAIssANcEs
• Des services d'évaluation des traitements sont financés actuellement dans la plupart des administrations au canada. • Dans le cadre de cette étude, on a constaté une adoption rapide et généralisée du service annuel Medscheck en Ontario. • Le nombre d'évaluations annuelles effectuées a augmenté avec le temps, mais peu de personnes ont reçu ce service plus d'une fois, ce qui pourrait représenter une occasion manquée. • Les évaluations annuelles Medscheck correspondaient généralement aux critères d'admissibilité au programme; toutefois, certaines constatations montrent possiblement que des patients moins complexes ont bénéficié des évaluations annuelles.
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Data analyses
The frequency distribution of number of MCAs per person over the 6-year period was calculated. All other analyses were stratified by age group (<66 and ≥66 years) and sex. Since all persons older than 65 years have prescription drug coverage under the ODB plan, we had access to most if not all of their prescription drug data (i.e., all drugs covered by the plan). We therefore examined this group separately. However, to ensure that a full year of data prior to the MCA was available to measure recipient characteristics, the cohort was split at age 66. Characteristics of MCA recipients were summarized using frequency distributions and proportions for categorical variables and means, medians, ranges and standard deviations for continuous variables.
Results
Program uptake
The Figure 1 also reveals a sharp increase in the number of MCA recipients beginning in the spring of 2010. Patterns of uptake were similar in both age groups. Between April 2007 and March 2013, 64% of recipients had 1 MCA while 36% of recipients had more than 1 MCA service. Those 66 years and Original research Original research over more frequently received multiple MCAs over the 6-year period compared with younger recipients (42% and 31%, respectively; Table 1 ). Less than 1% (n = 3073) of MCA recipients had 6 MCAs within the study period, although this finding needs to be interpreted with the consideration that not all claimants would have been eligible for an MCA during the entire 6 years of study.
Community pharmacy participation
Nearly 1500 pharmacies provided at least 1 MCA service within the first month the service was available. In the first year after launch, 3190 pharmacies provided at least 1 MCA. The number of participating pharmacies increased almost every year, with a sharper increase in 2010-2011 to 3505, followed by 3683 in 2012-2013.
Demographic characteristics of MCA recipients
Overall, 731,181 MCA recipients were younger than 66 years (7.1% were 65 years of age and 3.8% were younger than 25 years of age), and 767,259 were aged 66 years or older ( Figure 1 ; Table 2 ). Fifteen percent (n = 222,224) of MCA recipients were 80 years of age and over. We found that 31% of MCA recipients were not covered by the public drug plan. It is noteworthy that 25% of female recipients aged 66 years or older fell into the low-income group compared with 16% of male recipients in this age group (data not shown). Of MCA recipients, 11.2% were immigrants and 5.4% had been in Canada for fewer than 15 years. Furthermore, 88.4% of MCA recipients lived in urban centres. Urban centres reporting the highest number of MCA recipients were Toronto, Ottawa and Hamilton.
Health characteristics of MCA recipients
A high or very high level of morbidity was found in 25.2% of MCA recipients, and 87.8% had at least moderate morbidity ( Table 2 ). Specific comorbidities are identified in Table 3 . Hypertension was the most common diagnosis (67.9%). There was a higher prevalence of hypertension, heart failure and cancer among those aged 66 years and older compared with the younger cohort (Table  3) . Psychiatric conditions were more common in MCA recipients younger than 66 years compared with those 66 years and older. Rates of psychiatric conditions (30.9% vs 24.1%) and inflammatory conditions (29.5% vs 23.3%) were higher among women than men. Rates of cancer (13.7% vs 10.5%), heart failure (9.7% vs 6.9%) and diabetes (34.7% vs 26.7%) were higher among men vs women. Results were otherwise similar among men and women (data not shown).
Health care resource use Ten percent of MCA recipients visited an emergency department or were hospitalized within the 30 days prior to their first MCA. Thirty-eight percent of MCA recipients visited an emergency department or were hospitalized in the year prior to their first MCA; this prevalence rate was similar in recipients younger than 66 years (38.5%) and those 66 years of age and older (37.1%). The mean number of unique prescription drugs dispensed in the previous year for an MCA recipient 66 years of age and older was 11.3 (SD 6.3), and the mean number of unique prescription drugs dispensed on the same day as an MCA was 2. (Table 3 ).
Discussion
This is the first study of the Ontario MCA program that provides population-based data on program uptake. Over the first 6 years of the program, approximately 1 in 9 Ontarians received an MCA. The majority of recipients had hypertension or other types of cardiovascular disease.
Only one-third of recipients received the medication review service more than once despite the opportunity, depending on the year of their initial MCA, to have up to 6 MCAs within the analysis period. The low level of repeating MCA recipients reveals an important opportunity for pharmacists to better use the MCA service as a mechanism for consistently checking in with patients each year to help prevent and manage chronic disease. The number of MCAs delivered was fairly constant for the first 3 years but sharply increased in the spring of 2010. This was concurrent with the government announcement that professional allowances paid by generic companies to pharmacy owners for purchases of their drug products (rebates) would be phased out and that reimbursement for generic drugs would drop from 50% to 25% of the brand price effective July 2010. 14, 15, 23 This increase in MCA service delivery continued despite the funding of other MedsCheck services for diabetes, long-term care and homebound patients in the fall of 2010. 
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Almost half of Ontario pharmacies (1494/3132) made at least 1 MCA claim in the first month of the MC program (April 2007). 24 The rapid and widespread uptake of the service by pharmacies may be attributable to the $950 start-up payment provided by the ODB plan upon receipt of that pharmacy's first MCA claim. This payment was meant to acknowledge the time, effort and resources needed to enable delivery of MC services.
Common chronic conditions were well represented among MCA recipients, as expected from the eligibility requirements. The finding that 68% of MCA recipients had hypertension is consistent with population-based estimates from 1998 to 2008 that about 60% of Canadian residents aged 65 to 69 years are hypertensive. 25 Psychiatric conditions were more common in MCA recipients younger than 66 years compared with those 66 years and older. This finding was expected because about a third of recipients in the lower age group were receiving drug plan coverage because of low income or other social needs (e.g., Trillium, Ontario Works), a situation that is associated with mental health conditions. 26, 27 Also particularly interesting, 15% of MCA recipients were 80 years of age or older, which is lower than expected given that an analysis using the same data holdings showed that 42.6% of Ontarians aged 75 to 89 years had 3 or more common chronic conditions. 28 MCA recipients age 66 years and older were prescribed more medications on average than 2012 rates reported by the Canadian Institute for Health Information (CIHI); however, data from CIHI included all seniors, not just those on 3 or more chronic medications, so higher rates of prescription medication would be expected in MCA recipients. 29 Older recipients of an MCA had less emergency department use in the prior year (35%) compared with populationbased estimates from 2008-2009 (55.1%), which is possibly consistent with less complex patients despite being users of at least 3 chronic medications. 30 Notably, MCA recipients were dispensed approximately 3 unique prescription medications on the day they received the service, while those older than 66 years were dispensed more than 11 unique medications during the year before the service. This indicates a high likelihood that service delivery was consistent with program eligibility that dictates that recipients take at least 3 chronic medications. However, additional preliminary analyses have identified that the median number of unique prescriptions dispensed per year to MCA recipients older than 65 years is declining over time, 31 and further study is required to understand this trend and other changes in recipient characteristics over time.
Only 11% of MCA recipients were identified as immigrants, compared with the 28.3% of Ontarians recorded as immigrants in the 2006 census. Younger age, lower general use of health services by immigrants relative to the rest of the Canadian population 32, 33 and/or literacy barriers may be contributing to a lower rate of delivery of MCA services to immigrants.
Service specifications for publicly funded medication review programs in other provinces vary substantially. Ontario's MCA service is consistent with medication review programs in New Brunswick, Newfoundland and British Columbia (standard review) in that all include a medication reconciliation and adherence review. In contrast, programs in Saskatchewan, Alberta, Nova Scotia (advanced program) and British Columbia (consultation review) also require a pharmacotherapeutic review. Patient eligibility requirements also vary substantially across Canadian jurisdictions, 10 although programs in Prince Edward Island, Nova Scotia (basic), New Brunswick and Alberta are generally comparable to Ontario in this regard. The findings generated by this study will be more applicable to jurisdictions with adherence-focused programs and similar patient eligibility criteria. Other countries, including the United States, Australia, New Zealand and the United Kingdom, also fund various forms of medication reviews; however, the only published population-based data related to uptake of medication review services similar to MedsChecks comes from the Medication Use Review (MUR) program in England. In the first 2 years (2005-2007) of that program, MURs were provided by 65% of community pharmacies in England (n = 9872), revealing substantial uptake yet lower than the 95% uptake in Ontario. MUR claims rose steadily, with peaks at the end of each financial year, likely due to wanting to achieve the limit of 250 (ceiling in the first year) or 400 (the limit in subsequent years) per pharmacy per year set by the UK Department of Health. 34 The majority (75%) of all MUR claims were made by multiple (chain) pharmacies, with ownership type found
to be the most significant determinant of MUR uptake. Unfortunately, the current study is limited by lack of access to data on pharmacy ownership type, and so we were unable to describe ownership type MC uptake in Ontario.
There are a number of strengths to this study. The study leveraged linked administrative data that allowed for a detailed examination of recipient characteristics, including health resource utilization using well-validated data fields. It included all recipients over the period of study, and the patterns observed are consistent with fluctuations that can be explained by health policy changes. However, there are also a number of limitations to this study. The drug data available for the analyses were limited to beneficiaries of the ODB program, and so drug utilization in individuals receiving an MCA service who were aged 66 years or younger is available only for social assistance recipients. In addition, comparisons of MCA recipient characteristics with external population-based estimates are unbalanced because these estimates are generally not based on people approximating MCA eligibility criteria (i.e., 3 or more chronic medications). Also, this study did not explore the uptake of other MedsCheck services implemented in 2010 or any MedsCheck follow-up services. This will underestimate the number of people who had multiple MedsChecks over the 6-year period. Furthermore, the number of pharmacies providing MCA services is slightly overestimated, since a new pharmacy identifier is assigned when a pharmacy changes owner or location and the same pharmacy may be counted more than once. Finally, the study is also limited by the pooling of data from over a 6-year period, and consequently, the analysis does not address whether there are differences in recipient characteristics over time.
Conclusion
Over a 6-year period, approximately 1 in 9 Ontarians received an MCA, with the majority having cardiovascular disease. Service delivery increased over time; however, the number of persons receiving the service more than once was low. Results from this study have been used to inform analyses to compare MCA recipient characteristics over time and to identify predictors of use and outcomes of the MCA medication review service. ■
